Home | Welcome to Contract Pharma   
Last Updated Thursday, October 30 2014
Print RSS Feed

Financial Reports: Pfizer



By Gil Roth



Published July 30, 2013
Related Searches: Manufacturing Pharma Contract Manufacturing
Pfizer 2Q13

2Q Revenues: $13.0 billion (-7%)

2Q Earnings: $14.1 billion (+333%)*

YTD Revenues: $25.4 billion (-9%)

YTD Earnings: $16.9 billion (+234%)*

Comments: Lipitor sales worldwide dropped nearly $700 million in 2Q13 to $545 million (-55%), while overall pharma revenues fell $1.0 billion (-8%) to $12.1 billion. Lyrica posted a 10% gain to $1.1 billion, while changes in buying patterns led to a 3% drop for Prevnar vaccines ($970 million). New drugs Inlyta and Xalkori posted revenues of $71 million and $67 million, respectively. In its first quarter, Xeljanz reported $22 million in sales. The Pfizer CentreSource unit, which provides contract manufacturing and bulk pharma chemical sales, posted revenues of $63 million in the quarter, up 5%. PCS revenues for YTD are $116 million (+3%)

* Earnings include $10.5 billion (pre-tax) from spinning off its Zoetis Animal Health business.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On